Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

The six-minute walk test is a submaximal exercise test that can be performed even by a patient with heart failure not tolerating maximal exercise testing. To elucidate the clinical significance and prognostic value of the six-minute walk test in patients with primary pulmonary hypertension (PPH), we sought (1) to assess the relation between distance walked during the six-minute walk test and exercise capacity determined by maximal cardiopulmonary exercise testing, and (2) to investigate the prognostic value of the six-minute walk test in comparison with other noninvasive parameters. The six-minute walk test was performed in 43 patients with PPH, together with echocardiography, right heart catheterization, and measurement of plasma epinephrine and norepinephrine. Symptom-limited cardiopulmonary exercise testing was performed in a subsample of patients (n = 27). Distance walked in 6 min was significantly shorter in patients with PPH than in age- and sex-matched healthy subjects (297 +/- 188 versus 655 +/- 91 m, p < 0. 001). The distance significantly decreased in proportion to the severity of New York Heart Association functional class. The distance walked correlated modestly with baseline cardiac output (r = 0.48, p < 0.05) and total pulmonary resistance (r = -0.49, p < 0. 05), but not significantly with mean pulmonary arterial pressure. In contrast, the distance walked correlated strongly with peak V O(2) (r = 0.70, p < 0.001), oxygen pulse (r = 0.57, p < 0.01), and V E-VCO(2) slope (r = -0.66, p < 0.001) determined by cardiopulmonary exercise testing. During a mean follow-up period of 21 +/- 16 mo, 12 patients died of cardiopulmonary causes. Among noninvasive parameters including clinical, echocardiographic, and neurohumoral parameters, only the distance walked in 6 min was independently related to mortality in PPH by multivariate analysis. Patients walking < 332 m had a significantly lower survival rate than those walking farther, assessed by Kaplan-Meier survival curves (log-rank test, p < 0.01). These results suggest that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.

[1]  S J Jay,et al.  Reference equations for the six-minute walk in healthy adults. , 2000 .

[2]  Y. Okano,et al.  Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.

[3]  D L Sherrill,et al.  Reference equations for the six-minute walk in healthy adults. , 1998, American journal of respiratory and critical care medicine.

[4]  G. Roul,et al.  Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? , 1998, American heart journal.

[5]  H. Ross,et al.  Clinical, Hemodynamic, and Cardiopulmonary Exercise Test Determinants of Survival in Patients Referred for Evaluation of Heart Failure , 1998, Annals of Internal Medicine.

[6]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[7]  W. Stevenson,et al.  Six-minute walk test and heart rate variability: lack of association in advanced stages of heart failure. , 1997, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[8]  Y. Okano,et al.  Shortening of Doppler-derived deceleration time of early diastolic transmitral flow in the presence of pulmonary hypertension through ventricular interaction. , 1997, The American journal of cardiology.

[9]  P. Poole‐Wilson,et al.  Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. , 1997, Journal of the American College of Cardiology.

[10]  Y. Okano,et al.  Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.

[11]  G. Koch,et al.  Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension , 1997 .

[12]  L. Cahalin,et al.  The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. , 1996, Chest.

[13]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[14]  S. Rich,et al.  Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. , 1995, Journal of the American College of Cardiology.

[15]  J. Tamai,et al.  Delayed improvement in exercise capacity with restoration of sinoatrial node response in patients after combined treatment with surgical repair for organic heart disease and the Maze procedure for atrial fibrillation. , 1995, Circulation.

[16]  J. Sandoval,et al.  Survival in primary pulmonary hypertension. Validation of a prognostic equation. , 1994, Circulation.

[17]  Hakuo Takahashi,et al.  Estimation of Sulphoconjugated Catecholamine Concentrations in Plasma by High-Performance Liquid Chromatography , 1993, Annals of clinical biochemistry.

[18]  W. Gersony,et al.  Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. , 1991, Journal of the American College of Cardiology.

[19]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[20]  N. Reichek,et al.  Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. , 1989, Circulation.

[21]  M. Higginbotham,et al.  Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. , 1988, Circulation.

[22]  B. Groves,et al.  PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY , 1987 .

[23]  G. D'Alonzo,et al.  Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. , 1987, Chest.

[24]  B. Saltin,et al.  Maximal perfusion of skeletal muscle in man. , 1985, The Journal of physiology.

[25]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[26]  K. Wasserman,et al.  Contrasting cardiovascular and respiratory responses to exercise in mitral valve and chronic obstructive pulmonary diseases. , 1983, Chest.

[27]  A. Selzer,et al.  Reliability of the Determination of Cardiac Output in Man by Means of the Fick Principle , 1958, Circulation research.

[28]  Inda,et al.  A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .